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Hepatitis C virus (HCV) glycoproteins E1 and E2, when expressed in eukaryotic cells, are retained in the
endoplasmic reticulum (ER). C-terminal truncation of E2 at residue 661 or 715 (position on the polyprotein)
leads to secretion, consistent with deletion of a proposed hydrophobic transmembrane anchor sequence. We
demonstrate cell surface expression of a chimeric glycoprotein consisting of E2 residues 384 to 661 fused to the
transmembrane and cytoplasmic domains of influenza A virus hemagglutinin (HA), termed E2661-HATMCT.
The E2661-HATMCT chimeric glycoprotein was able to bind a number of conformation-dependent monoclonal
antibodies and a recombinant soluble form of CD81, suggesting that it was folded in a manner comparable to
“native” E2. Furthermore, cell surface-expressed E2661-HATMCT demonstrated pH-dependent changes in
antigen conformation, consistent with an acid-mediated fusion mechanism. However, E2661-HATMCT was
unable to induce cell fusion of CD81-positive HEK cells after neutral- or low-pH treatment. We propose that
a stretch of conserved, hydrophobic amino acids within the E1 glycoprotein, displaying similarities to flavivirus
and paramyxovirus fusion peptides, may constitute the HCV fusion peptide. We demonstrate that influenza
virus can incorporate E2661-HATMCT into particles and discuss experiments to address the relevance of the
E2-CD81 interaction for HCV attachment and entry.
Enveloped viruses acquire their lipid membranes by budding
through host cellular membranes (reviewed in reference 35).
The majority of enveloped viruses bud at the plasma mem-
brane. However, several viruses assemble and bud at internal
membranes such as those of the endoplasmic reticulum (ER)
(e.g., rotaviruses), ER-Golgi intermediate compartments (e.g.,
coronaviruses), or the Golgi complex (e.g., bunyaviruses). This
behaviour generally reflects the targeting of the viral glycop-
roteins (gps) within subcompartments of the ER or Golgi com-
plex. In the latter cases, viruses are released from infected cells
either by cell lysis or after transport through the cellular se-
cretory pathway to the cell surface.
Hepatitis C virus (HCV), the major cause of non-A, non-B
hepatitis, is an enveloped virus classified in the Flaviviridae
family (reviewed in references 3 and 39). The genome encodes
two putative envelope gps, E1 (polyprotein residues 192 to
383) and E2 (residues 384 to 746), which are released from the
viral polyprotein by signal peptidase cleavage(s) (13, 18, 43).
Both gps are heavily modified by N-linked glycosylation and
are believed to be type I integral transmembrane proteins, with
C-terminal hydrophobic anchor domains.
Expression of the E1E2 gps in mammalian cell lines dem-
onstrates their ER retention with no cell surface gp expression
detectable (8, 37, 46, 47). Immunoelectron microscopic studies
localized the gps to the ER (7, 8). We (10) and others (4)
reported the presence of ER retention “signals” within the
C-terminal regions of both E1 and E2 gps, explaining these
observations. Consistent with these data, truncation of E2 at its
C terminus leads to its secretion from expressing cells (26, 29,
30, 45, 47). These observations are consistent with a model of
HCV particle morphogenesis occurring by budding into the
ER, as reported for other members of the Flaviviridae.
When expressed in tissue culture cells, the E1 and E2 gps
interact to form noncovalently linked complexes, whose size is
consistent with E1E2 heterodimers (6, 8). In addition to these
noncovalently associated E1E2 complexes, a significant pro-
portion of E1 and E2 are present in disulfide-linked aggre-
gates, which are believed to result from a nonproductive fold-
ing pathway (1a, 6, 8, 13). Since HCV cannot be propagated
efficiently in vitro, it has been difficult to study “native” E1E2
gp forms as they exist on the virus particle. It is critical when
studying the biological activity of the HCV gps to distinguish
between molecules that undergo productive folding and assem-
bly and those that follow a nonproductive pathway(s) resulting
in misfolding and aggregation (7). Recently, Dubuisson and
colleagues reported a number of conformation-dependent
monoclonal antibodies (MAbs) (H2 and H53) which specifi-
cally recognize nondisulfide-bridged E2, both alone and when
complexed with E1, allowing the study of gp complexes which
may represent “native” prebudding forms of the HCV gp com-
plex (4, 6, 30).
gps exposed on the virus surface mediate entry into target
cells. This process requires binding of the virus particle to a
receptor(s) present at the surface of the host cell, followed by
fusion of the viral and cellular membranes. For viruses such as
influenza virus and the flavivirus tick-borne encephalitis virus,
particles internalize after receptor binding and fuse with the
endosomal membranes. The low pH within the endosomal
compartment induces a major structural rearrangement of the
gps, resulting in exposure of a fusion peptide which destabilizes
membranes, leading to fusion (reviewed in references 11, 17,
and 50). The mechanism by which HCV enters target cells is
currently unknown; however, the E2 gp is thought to be re-
sponsible for initiating virus attachment to a receptor on po-
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tential host cells (42). Indeed, a soluble form of a C-terminally
truncated E2 gp was used to identify CD81 as a putative re-
ceptor for HCV (36). CD81 is a broadly expressed protein and
is reported to be involved in a variety of biological responses
including adhesion, morphology, proliferation, activation, and
differentiation of T-, B-, and other cell types (reviewed in
reference 23).
Generation of viral pseudotypes is one of the most widely
used methods for assaying functional receptors, allowing at-
tachment, penetration, and uncoating to be studied. Recent
reports that vesicular stomatitis virus (VSV) expressing chi-
meric HCV E2 gps, comprising the putative E2 ectodomain
fused to the transmembrane and cytoplasmic domains of VSV
G protein, allowed entry into target cells suggested that the
ectodomain of E2 was sufficient to confer viral attachment and
entry (22, 28). We were interested in studying the antigenic
conformation of E2 expressed at the cell surface and whether
such a protein was able to induce CD81-dependent cell fusion.
Here, we demonstrate cell surface expression of a chimeric gp
consisting of E2 residues 384 to 661 fused to the transmem-
brane and cytoplasmic domains of influenza A virus hemag-
glutinin (HA) (E2661-HATMCT). These data are consistent with
a previous report demonstrating cell surface expression of
truncated versions of E2 fused to the transmembrane domain
of CD4 or a glycosylphosphatidylinositol anchor (4). The
E2661-HATMCT chimeric gp was able to bind a number of
conformation-dependent MAbs and a recombinant soluble
form of CD81, suggesting that it was folded in a manner com-
parable to that of native E2. Furthermore, cell surface-ex-
pressed E2661-HATMCT demonstrated pH-dependent changes
in antigen conformation, consistent with an acid-mediated fu-
sion mechanism. However, E2661-HATMCT was unable to in-
duce cell fusion of CD81-positive HEK cells after neutral- or
low-pH treatment. We demonstrate that influenza virus can
incorporate E2661-HATMCT into particles and discuss possible
experiments to address the relevance of the E2-CD81 interac-
tion for HCV attachment and entry.
MATERIALS AND METHODS
Materials. MAbs specific for E1 (3/8d and 3/8ow), E2 (1/39, 6/82a, and 6/16),
CD81 (5A6 [33]), and glutathione S-transferase (GST) (2/18) were raised by
standard procedures. MAbs specific for conformation-dependent epitopes (H2,
H31, H33, H44, H50, H53, H60, and H61) were a gift from J. Dubuisson (Institut
Pasteur, Lille, France). MAbs specific for influenza A virus NP and fluorescein
isothiocyanate (FITC)-, phycoerythrin (PE)- and horseradish peroxidase (HRP)-
conjugated antibodies were purchased from Harlan Sera-Labs. The MAb against
MHC class I was purchased from Sigma. Enzymes used for cloning were pur-
chased from Gibco-BRL Life Technologies or New England Biolabs. Dulbecco’s
minimum essential medium (DMEM), fetal calf serum (FCS), HEPES, and
L-glutamine were obtained from Gibco-BRL Life Technologies.
Construction of recombinant cDNA. A cDNA cassette allowing replacement
of the ectodomain or transmembrane and cytoplasmic domains of influenza A
virus HA was constructed. Unique restriction sites were introduced into the
cDNA of HA by PCR mutagenesis. PCR was carried out with sense (W5506;
59-TCTGGATACAAAGACTGGGCCCTGTGGATTTCCTTTGCC-39) and
antisense (W5501; 59-GGGCCCCTGCAGGTCGACTCAAATGCAAATGTT
GCA-39) primers on the plasmid pGEM11HA template (X-31 strain; kindly
supplied by D. Steinhauer, National Institute for Medical Research, London,
United Kingdom). The resulting product was used as a primer in a secondary
reaction with sense primer (W5502; 59-GGGCCCGATATCAGCAAAAGCAG
GGGATAATTC-39) with pGEM11HA as the template. The product of this
secondary reaction was digested with EcoRV and PstI and ligated with pBlue-
script SK(1) (Stratagene) similarly digested. DNA sequencing of the resulting
plasmid, designated pBS1HA/CAS, confirmed the introduction of the unique
restriction sites. The vector pCDM8 (Invitrogen) was used for expression in
eukaryotic cells. The ApaI site within the polyomavirus ori of pCDM8 was
destroyed through digestion with ApaI, treatment with T4 DNA polymerase, and
self-ligation to form pCDM8(2ApaI). Plasmid pBS1HA/CAS was digested with
HindIII and PstI. This fragment was ligated with pCDM8(2ApaI) similarly
digested, to form plasmid pCDM8(2ApaI)1HA/CAS(HindIII-PstI). This plas-
mid was used to generate the fusion protein between the E2 and HA transmem-
brane and cytoplasmic domain sequences. HCV E2 sequence was amplified by
PCR with plasmid pBRTM/HCV1-3011 (kindly supplied by C. M. Rice, Wash-
ington University, St. Louis, Mo.) as the template. The sequence encoding HCV
residues 364 to 661 was amplified with sense (E2/FWD; 59-GCGCAAGCTTCC
ATGGTGGGGAACTGG-39) and antisense (Y0704; 59-TATATAGGGCCCC
CTCGGACCTGTCCCTGTC-39) primers, while the sequence encoding HCV
residues 364 to 715 was amplified with the same sense primer and the antisense
primer Y0705 (59-TATATAGGGCCCCCTTAATGGCCCAGGACGCG-39).
Both these PCR products were digested with HindIII and ApaI and ligated with
pCDM8(2ApaI)1HA/CAS (HindIII-PstI), similarly digested. The resulting
plasmids were designated pE2661-HATMCT and pE2715-HATMCT. Corresponding
vectors also encoding E1 sequence were generated. Primers Y0699 (59-GCGA
GCAAGCTTCCATGGGTTGCTCTTTCTCTATC-39) and Y0704 were used in
PCR with pBRTM/HCV1-3011 as the template. The product of this reaction was
digested with HindIII and ApaI and ligated with pCDM8(2ApaI)1HA/CAS
(HindIII-PstI) similarly digested to form the plasmid pE1E2661-HATMCT. To
construct pE1E2715-HATMCT, pE1E2661-HATMCT was digested with HindIII and
SapI and ligated with pE2715-HATMCT similarly digested. Plasmid pE1E2, en-
coding the full sequence of E1 and E2, with the endogenous signal peptide, was
constructed by PCR amplification with Y0699 and Y5862 (59-GATATCCTGC
AGTCACGCCTCCGCTTGGGATATGAG-39), using pBRTM/HCV1-3011 as
the template. The product of this reaction was digested with HindIII and PstI and
ligated with pCDM8(2ApaI) similarly digested. Plasmid pE2 was constructed by
PCR of the E2 sequence with E2/FWD primer and Y5862 with pBRTM/HCV1-
3011 as the template. The product of this reaction was digested with HindIII and
PstI. As a result of the cloning strategy described here, each recombinant chi-
meric protein possesses an additional Gly-Ala amino acid pair at the junction of
the ectodomain (E2 sequence) and transmembrane domain (HA sequence).
Indirect immunofluorescence. HEK (293) cells were grown in DMEM sup-
plemented with 10% FCS and 2 mM L-glutamine. Subconfluent monolayers
grown in 100-mm-diameter dishes were transfected with 10 mg of plasmid by the
calcium phosphate coprecipitation method. Precipitates were incubated with
cells for 4 h at 37°C before being replaced with DMEM containing 2% FCS. At
48 h posttransfection, the cells were washed once with phosphate-buffered saline
(PBS), fixed with 3% paraformaldehyde for 30 min at room temperature, washed
with PBS, quenched with 10 mM glycine in PBS for 10 min at room temperature,
washed, and permeabilized with 0.1% Triton X-100 in PBS. The permeabiliza-
tion step was omitted for measurements of surface immunofluorescence. Cells
were incubated with PBS containing 1% FCS and 0.05% sodium azide (P/F/A)
and then incubated with primary antibodies for 1 h at room temperature. Cock-
tails of anti-E1 (3/8d and 3/80w) or anti-E2 (1/39, 6/82a, and 6/16) MAbs were
used. After incubation with primary antibodies, the cells were washed twice with
P/F/A, incubated with FITC-conjugated anti-mouse or anti-rat antibodies (at
1/500 dilution) for 1 h at room temperature, and washed three times with P/F/A.
Immunofluorescence was visualized under an Axiovert 135 fluorescence micro-
scope (Zeiss).
Expression and purification of GST-CD81EC2. The human CD81 EC2 was
made from a gel-purified HincII-RsaI fragment, coding for amino acids 116 to
202, of the cDNA clone and ligated to pGEX-2T (Pharmacia) which had been
cut with EcoRI and blunted with T4 polymerase. The pGST-CD81EC2 construct
was examined by sequencing to confirm the orientation and absence of muta-
tions. SURE Escherichia coli (Stratagene) transformed with the plasmid was
induced with 0.1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) and harvested
after 3 h by centrifugation, and the pellet was lysed by sonication. The GST-
CD81EC2 fusion protein was recovered by affinity chromatography on glutathi-
one-Sepharose 4B (Pharmacia). The purified fusion protein reacted with the
anti-CD81 MAbs 5A6 and 1D6 when unreduced as determined by Western
blotting. As noted for cellular CD81, the reduced recombinant fusion protein did
not react with the antibodies (1).
Flow-cytometric analysis. HEK cells were transfected as described above. At
48 h posttransfection, the cells were harvested with PBS containing 0.2 mM
EDTA and washed with PBS twice. They were incubated for 30 min at room
temperature in PBS containing 1% FCS and 0.05% sodium azide (P/F/A). Via-
ble-cell counts were determined (trypan blue exclusion), and the cells were
resuspended at 107/ml in P/F/A. A total of 106 cells were incubated with 100 ml
of primary antibodies (anti-E2 linear MAbs; 1/39, 6/82a, and 6/16 equal volumes
of tissue-culture supernatant or anti-E2 conformational MAbs; H2, H31, H33,
H44, H50, H53, H60, and H61 at 10 mg/ml, kindly supplied by J. Dubuisson,
Institut Pasteur de Lille) or with 100 ml of recombinant CD81 protein, diluted in
P/F/A for 1 h at room temperature. The cells were washed three times with P/F/A
before addition of 100 ml of PE-conjugated secondary antibody (at 1/100 dilu-
tion). Experiments assessing the binding of GST fusion proteins to transfected
cells included an additional incubation with an anti-GST MAb (100 ml of tissue-
culture supernatant). After incubation for 1 h at room temperature, the cells
were washed three times with P/F/A and analyzed with a FACScan apparatus.
The data were processed with CellQuest software (Becton Dickinson).
Cell-cell fusion assay. HEK cells were infected with influenza A virus
A/WSN/33 at a range of multiplicities of infection in serum-free DMEM for 7 h
at 37°C. The virus inoculum was removed, and the cells were incubated for 1 h
at 37°C with DMEM containing 1% FCS. The cells were washed free of FCS,
incubated for 3 min at room temperature in PBS containing 10 mM morpho-
lineethanesulfonic acid (MES) and 10 mM HEPES at either pH 5.0 or pH 7.0,
washed with PBS, and incubated at 37°C in DMEM containing 2% FCS. Trans-
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fected cells were treated similarly. Following overnight incubation, the cells were
fixed with methanol-acetone and E2 or NP antigen was visualized by indirect
immunofluorescence as described above. To visualize nuclear DNA, a mountant
containing propidium iodide (Vectashield; Vector Laboratories) was used. The
cells were visualized with a confocal microscope (Bio-rad).
Generation and analysis of pseudotyped influenza viruses. COS-7 cells were
electroporated either with empty vector, pCDM8, or with 15 mg of plasmid
pE2661-HATMCT as described elsewhere (2). Following electroporation, the cells
were resuspended in DMEM containing 10% FCS and 10 mM HEPES (pH 7.4)
and allowed to recover at 37°C overnight. They were then infected with influenza
A virus A/PR8/34 at a multiplicity of infection of 3. After 24 h, supernatants were
collected and clarified of cellular debris by centrifugation at 15,000 rpm in a
Beckman SW55 rotor. To confirm that the released virus contained the E2661-
HATMCT protein, virus was purified by centrifugation at 45,000 rpm in a Beck-
man SW55 rotor through a 1-ml cushion of 30% sucrose in NTE (100 mM NaCl,
10 mM Tris-HCl [pH 7.8], 1 mM EDTA). Virus pellets were resuspended in 10
ml of NTE and subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and Western blotting to detect the incorporation of
E2661-HATMCT into particles. Cell lysates were generated by lysis of transfected
COS-7 cells, or MDCK cells stably expressing the A/WSN/33 M2 protein, grown
to confluency in 35-mm-diameter dishes. The cells were washed once in ice-cold
PBS and incubated with lysis buffer (100 mM NaCl, 50 mM iodoacetamide, 1%
Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, 20 mM Tris HCl [pH 7.5])
on ice for 10 to 30 min. After SDS-PAGE, the E2 antigen was detected by
Western blotting with rat anti-E2 MAbs followed by an anti-rat HRP-conjugated
secondary antibody. The influenza A virus M2 protein was detected by using a
mouse MAb, 14C2 (kindly supplied by R. A. Lamb, Northwestern University,
Evanston, Ill.), followed by an anti-mouse HRP-conjugated secondary antibody.
Proteins were visualized following exposure to enhanced chemiluminescence
detection reagents (Amersham Life Sciences) and photographic film.
RESULTS
Truncated E2 with transmembrane and cytoplasmic do-
mains of influenza virus HA is expressed at the cell surface.
Since C-terminal truncation of E2 results in protein secretion
from the cell (29, 30, 45, 47), we reasoned that addition of a
transmembrane domain to such a truncated form may result in
localization at the plasma membrane. To test this hypothesis,
cDNA encoding the chimeric gps was constructed, consisting
of the E2 ectodomain (from amino acids 384 to 661 or 715)
fused to the transmembrane and cytoplasmic domains of in-
fluenza A virus HA (Fig. 1). Since the E2 gp acts as a chap-
erone for E1 folding (30), we were interested in determining
any effects of coexpression of the full-length E1 protein on
both E1 and E2 localization. Plasmids encoding both E1 and
the chimeric E2 gps were therefore constructed (Fig. 1). All
plasmids contained endogenous signal sequences to direct
translocation to the ER, including polyprotein residues 364 to
383 for E2 chimeras and 171 to 191 for E1-encoding plasmids.
HEK (293) cells were transfected with the plasmids shown in
Fig. 1, and 48 h posttransfection the cells were fixed, with or
without Triton X-100 permeabilization, to monitor internal
and cell surface-expressed antigen, respectively. Indirect im-
munofluorescence was performed with MAbs specific for both
E1 and E2 proteins. The results are summarized in Table 1. As
expected, full-length E1 and E2 could not be detected at the
cell surface whereas E2661-HATMCT could be detected. Coex-
pression of E1 did not result in E1 expression at the cell
surface, nor did it have any detectable effect(s) on E2661-
HATMCT cell surface expression. When E2715-HATMCT was
expressed, weak fluorescence could be detected both intracel-
lularly and at the cell surface, suggesting that E2715-HATMCT
was expressed less efficiently than E2661-HATMCT. Similar re-
sults were obtained when E2 expression was quantified by
analysis of transfected cells by flow cytometry (data not
shown). The reduced expression of the E2715-HATMCT gp is
consistent with previous observations about the secretion of
E2, truncated at residue 715 relative to 661, and may relate to
the folding efficiency of the truncated proteins (4, 26, 30).
Recognition of cell surface E2 by conformation-dependent
anti-E2 MAbs: the effect of low-pH treatment. We were inter-
ested in determining if cell surface-expressed E2661-HATMCT
was recognized by MAbs reported to specifically interact with
correctly folded E2 (4, 6). HEK cells were transfected with
pE2661-HATMCT and with control empty vector and at 48 h
posttransfection were assayed for their ability to bind a panel
of MAbs specific for linear and conformation-dependent
epitopes. MAb recognition of transiently expressing cells was
analyzed by flow cytometry. All of the conformation-depen-
dent MAbs (H2, H31, H33, H44, H50, H53, H60, and H61)
were able to recognize the chimeric gp, with mean fluorescence
intensities in the range of 85.3 to 220.3 for E2-expressing cells
stained in PBS and with background values for mock-trans-
fected cells of 4.5 to 9.3 (data not shown and Fig. 2). These
data suggest that the chimeric E2 gp is expressed in a confor-
mation similar to that suggested for native E2 and may there-
fore be considered an accurate model of E2 expressed on HCV
virions.
The entry of flaviviruses into cells is believed to occur by an
FIG. 1. Schematic representation of the proteins expressed in these studies.
HCV E1 or E2 sequences were fused to the transmembrane and cytoplasmic
domains of influenza A virus HA protein. The amino acid position on the HCV
polyprotein is indicated above the bars. Signal sequences are indicated by solid
boxes, while the HA sequence is shown by hatching. These chimeric proteins
were cloned in the eukaryotic expression vector pCDM8.
TABLE 1. Summary of indirect immunofluorescence observed for
E1 and E2 localization on transiently expressing cells.
Plasmid
Fluorescence intensity witha:
Anti-E1 Anti-E2
Internal Surface Internal Surface
Vector 2 2
pE2 111 2
pE1E2 111 2 111 2
pE2661-HATMCT 111 111
pE1E2661-HATMCT 111 2 111 111
pE2715-HATMCT 111 11
pE1E2715-HATMCT 111 2 111 11
a The intensity of fluorescence across a number of fields is indicated.
6784 FLINT ET AL. J. VIROL.
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acid-mediated fusion mechanism, with conformational chang-
e(s) being detectable in the envelope gp E after exposure to
low pH (14, 16, 20, 40). To determine if a similar mechanism
might operate for HCV, E2661-HATMCT-expressing cells were
incubated at pH 5 or 7 for 15 min, washed twice, resuspended
in PBS, and assayed for their ability to bind the conformation-
dependent MAbs. As controls, MHC class I and CD81 expres-
sion were monitored and the MAbs were shown to bind equiv-
alently independent of the pH treatment (data not shown).
Most of the MAbs bound to the pH 7- or 5-treated cells
equivalently, with the exception of MAbs H44 and H50 (data
not shown and Fig. 2). MAb H44 failed to recognize pH 5.0-
treated E2661-HATMCT, and recognition by H50 was reduced
after pH 5.0 treatment (Fig. 2). Since the cells were resus-
pended in PBS after being treated at pH 5.0 or 7.0, the
conformational change(s) that occurred was irreversible.
Similar results were observed by enzyme-linked immunosor-
bent assay for MAb recognition of low-pH-treated soluble
E2661 gp (data not shown). These data are consistent with
reports regarding the sensitivity of the flavivirus gp E to low
pH treatment.
E2661-HATMCT binds recombinant CD81, a putative recep-
tor for HCV. Recently, CD81 has been identified as a putative
receptor for HCV (36). Binding of E2 to cells may be blocked
by a recombinant fusion protein containing the second extra-
cellular loop (EC2) of CD81 (9, 36). It was of interest, there-
fore, to determine if cell surface-expressed E2661-HATMCT
could bind a recombinant form of CD81, GST-CD81 contain-
ing the EC2. This GST-CD81EC2 protein is able to bind a
number of conformation-dependent CD81 specific MAbs and
to inhibit the interaction of soluble E2 with CD81-positive cells
(9). HEK cells were transfected with either pE2661-HATMCT or
empty vector and at 48 h posttransfection were monitored for
both E2 expression and the ability to bind GST-CD81EC2 and
a control protein, GST-nef. FACScan analysis demonstrated
that 25% of the cells expressed E2 at their surface (Fig. 3A)
and that a percentage of these cells were able to bind GST-
CD81EC2. No significant binding of GST-nef to cells trans-
fected with vector or with pE2661-HATMCT was detected.
When GST-CD81EC2 (20 mg/ml) was incubated with mock-
transfected cells, a low-level binding was observed (2.1% pos-
itive cells); however, a higher level of GST-CD81EC2 cell
binding was detected for cells expressing E2661-HATMCT, i.e.,
10.8% (Fig. 3B). Similar results were observed with a reduced
concentration of GST-CD81EC2 (5 mg/ml). These figures are
lower than the percentage of cells expressing E2661-HATMCT
on their surface, possibly because GST-CD81EC2 binding was
not saturated or because the affinity of the anti-GST MAb for
the cell-bound GST-CD81EC2 was lower than that of the
anti-E2 MAbs for E2. However, we cannot exclude the possi-
bility that the EC1 loop of CD81 (lacking from this recombi-
nant fusion protein) influences the affinity of EC2 for E2.
These data confirm that cell surface-expressed chimeric E2 can
bind a recombinant form of CD81, with the binding site resid-
ing between residues 384 and 661, and that E2661-HATMCT is
active in the (putative) receptor-binding function.
E2 at the cell surface does not induce acid-mediated cell-cell
fusion. Fusion of cells expressing influenza virus HA protein by
acid treatment has been well characterized (reviewed in refer-
ences 11, 17, and 50). Since flaviviruses have been reported to
enter cells via receptor-mediated endocytosis, we were inter-
ested in determining if E2661-HATMCT could induce cell-cell
fusion in CD81-positive cells after acid treatment. HEK and
the glial cell line, U87, were shown to express CD81 with mean
fluorescence intensities of 958.4 and 120.3, respectively, by
using the CD81-specific MAb 5A6, whereas an irrelevant iso-
type-matched control MAb gave values of 8.9 and 12.3 (data
not shown). HEK cells transiently expressing E2661-HATMCT
were treated at pH 5.0 or 7.0 as detailed above and incubated
at 37°C overnight. E2-expressing cells were detected by indi-
rect immunofluorescence, using MAbs 1/39, 6/82, and 6/16, and
the nuclei were visualized with propidium iodide. After neu-
tral- or low-pH treatment, no cell-cell fusion of cells expressing
E2 at their surface was observed (Fig. 4C). As a positive con-
trol for the assay, HEK cells were infected with influenza A
virus strain A/WSN/33 at different multiplicities of infection.
This strain was chosen because cleavage of HA0 to HA1 and
HA2, a necessary prelude to fusion, does not require trypsin
treatment. Influenza virus-infected cells were identified by us-
ing an antibody specific for nucleoprotein (NP). Influenza vi-
rus-mediated cell fusion was easily detected, with large syncytia
forming around NP-positive cells following low-pH treatment
(Fig. 4B) but not after neutral-pH treatment (Fig. 4A). The
syncytia were most evident at high multiplicities of infection, in
line with previous observations that membrane fusion may be
dependent upon the local density of fusion protein (5). How-
ever, the U87 glial cell line is a more sensitive indicator cell for
studying both influenza virus- and human immunodeficiency
virus-mediated cell fusion (24); hence, the experiment detailed
above with E2661-HATMCT was repeated in this cell line. Com-
parable results were obtained, such that no E2661-HATMCT-
mediated cell fusion was observed; however, influenza virus-
FIG. 2. Conformation of cell surface E2661-HATMCT. HEK cells were trans-
fected with control empty vector (solid histograms) or with pE2661-HATMCT
(empty histograms). At 48 h posttransfection, cells were harvested and treated
with pH 5.0 or 7.0 buffer. Cells were washed, resuspended in PBS, and immu-
nostained with MAb H53, H44, or H50. Bound antibody was detected with
PE-conjugated rabbit anti-mouse immunoglobulin antibody and flow cytometry.
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induced fusion was observed at all multiplicities of infection
tested (data not shown). These data indicate that under con-
ditions which support cell-cell fusion by the influenza virus HA
protein, the chimeric E2661-HATMCT gp does not induce any
detectable cell fusion.
E2661-HATMCT can be incorporated into influenza virus par-
ticles. Influenza A viruses do not incorporate significant levels
of host cell proteins into their envelopes. However, possession
of HA transmembrane and cytoplasmic tail sequences has
previously been shown to direct the incorporation of foreign
proteins into influenza virus particles (31, 52). Since E2661-
HATMCT was expressed at the cell surface and contained the
relevant HA sequences, we tested the ability of influenza A
virus to incorporate the chimeric gp expressed in COS cells. It
is important to note that we (9) and others (36) have previously
shown that E2 is unable to bind to COS-expressed CD81, such
that high level expression of E2661-HATMCT can be achieved
without receptor ligand complex formation. COS-7 cells were
electroporated with pE2661-HATMCT (Fig. 5A and B, lanes 2
and 4) or empty vector (lanes 1 and 3). Cells were infected with
influenza virus 24 h after transfection (multiplicity of infection,
3; lanes 1 and 2), and the extracellular progeny virus was
harvested after a further 24 h. Virions were separated from
host cell membrane fragments by ultracentrifugation through a
high-density sucrose cushion and characterized for their con-
stituent proteins by Western blotting. The influenza virus pro-
tein M2, a minor component of influenza virus, was visible,
confirming the presence of influenza A virus particles derived
from infected cells (Fig. 5B). E2 antigen was detected in a
lysate derived from pE2661-HATMCT-transfected cells (Fig. 5A,
lane 4), indicating that expression had occurred in these cells.
Furthermore, this protein was incorporated into influenza vi-
rus particles, since it was present in progeny virions from cells
transfected with pE2661-HATMCT (Fig. 5A, lane 2). The E2661-
HATMCT in a lysate of expressing cells and that incorporated
into influenza virus virions was compared (Fig. 5C). Since
influenza virus virions bud through the plasma membrane, the
chimeric molecule would be expected to undergo modification
with complex glycans during transport through the secretory
transport system. Consistent with this, the E2661-HATMCT
present in a lysate from expressing cells migrated more rapidly
in SDS-PAGE (Fig. 5C, lane 1) than did that present in influ-
enza virus virions (lane 2).
FIG. 3. E2661-HATMCT binds recombinant CD81. (A) Expression of E2661-HATMCT on transfected HEK (293) cells. Cells were transfected with pE2661-HATMCT
or with control empty vector. At 48 h posttransfection, the cells were immunostained with rat anti-E2 antibodies followed by PE-conjugated rabbit anti-rat
immunoglobulin and were subjected to flow cytometric analysis. The results are presented as dot plots of forward scatter (FSC) against PE fluorescence in the FL2
channel. The percentage of E2-positive cells is indicated. (B) Binding of GST-CD81EC2 to E2661-HATMCT-expressing cells. HEK (293) cells were transfected with
control empty vector or with pE2661-HATMCT. At 48 h posttransfection, the cells were incubated with no GST fusion protein, GST-nef, or GST-CD81EC2 at the
concentrations indicated. Bound GST fusion protein was detected with a rat anti-GST MAb (2/18) followed by a PE-conjugated rabbit anti-rat immunoglobulin
antibody. The percentage of positive cells is indicated below each plot.
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DISCUSSION
The current understanding of HCV gp function is limited by
the lack of a tissue culture system supporting efficient replica-
tion of the virus. From studies with transient-expression sys-
tems, it is believed that gps E1 and E2 localize to the ER in
infected cells (4, 6, 8). By analogy to other flaviviruses, virus
morphogenesis may involve budding into the ER and subse-
quent transport of viral particles through the host cell secretory
pathway before release into the extracellular space. Modifica-
tion of flavivirus E and prM protein glycans by trimming and
terminal addition suggests that virions do indeed move through
an exocytosis pathway similar to that used for host gps (27, 32).
In this report we describe a truncated form of the HCV E2
gp fused to the transmembrane and cytoplasmic domains of
the influenza A virus HA protein. This chimeric protein was
expressed at the cell surface, where it was able to bind a
number of conformation-dependent MAbs and a recombinant
soluble version of the putative HCV receptor, CD81 (Table 1;
Fig. 2 and 4). These data suggest that the chimeric gp is folded
in a manner comparable to E2 present in native E1E2 com-
plexes and that it is in a form able to bind the putative receptor,
CD81. Low-pH treatment of cell surface-expressed E2 resulted
in a conformational change(s). However, neutral- or low-pH
treatment of CD81-positive cells expressing the chimeric gp at
the cell surface did not result in cell fusion.
If HCV virions are indeed transported through the host cell
secretory pathway, then E2661-HATMCT should resemble E2
on the surface of virions. Understanding the way in which E2
is glycosylated may help our understanding of E2 conformation
and structure. Inhibition of core glycosylation by tunicamycin
prevents E2 from folding correctly and being recognized by the
conformation-dependent MAbs (1a). Since E2661-HATMCT re-
acts with such MAbs and since H2 and H53 react with nonco-
valently associated E1E2 heterodimers (4, 6), this indicates
that E2661-HATMCT has a conformation similar to that
adopted in E1E2 complexes.
A proteolytic cleavage is a common posttranslational mod-
ification of viral membrane proteins (reviewed in reference
21). For example, during virion transit, the prM protein of
flaviviruses is cleaved by the host protease furin within a post-
Golgi acidic compartment (15, 38, 48). This cleavage is re-
quired for the acquisition of virion infectivity. No proteolytic
cleavage was detectable in deglycosylated E2661-HATMCT,
since no size differences were observed when expressing cells
were treated with or without brefeldin A, an inhibitor of the
secretory transport system (data not shown). This suggests
that, unlike prM, HCV E2 does not undergo proteolytic cleav-
age as a step in virus maturation.
Previous work has shown that truncation of E2 to residue
661 results in a molecule that is more readily exported from
the cell than is a molecule truncated at residue 715 (4, 26,
30). The additional residues could reduce the efficiency of
E2 folding and hence of secretory transport. Our data is
consistent with this hypothesis, since E2661-HATMCT was de-
tected more readily on the surface of expressing cells than was
E2715-HATMCT (Table 1). Given the reported chaperone role
of E2 in E1 folding, we were interested in determining whether
FIG. 4. Cell-cell fusion is not mediated by E2661-HATMCT under conditions
which permit HA-mediated fusion. HEK cells were infected with influenza A
virus (A and B) or transfected with plasmid pE2661-HATMCT (C). Cell mono-
layers were treated at pH5.0 (B and C) or pH 7.0 (A) and visualized by indirect
immunofluorescence with anti-E2 antibodies for transfected cells, or anti-NP
MAb for influenza virus-infected cells, with propidium iodide to visualize nuclei.
These micrographs show representative fields from the examined samples.
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cell surface expression of E2661-HATMCT would lead to expres-
sion of E1 at the cell surface (30). However, E1 was not
detected at the cell surface under any circumstances; further-
more, E1 coexpression did not affect the level of E2 transport
to the plasma membrane.
It is thought that after receptor-mediated endocytosis, flavi-
virus entry into target cells proceeds via an acid-mediated
fusion event, where the viral envelope fuses with an endosomal
membrane. Acid treatment of the flavivirus envelope protein E
in mature virions results in a conformational change (14, 16,
20, 40). This conformational change is irreversible and results
in the exposure of new antigenic epitopes and the loss of
others. Treatment of cell surface-expressed E2661-HATMCT
with pH 5.0 buffer caused an irreversible conformational
change recognized by MAbs H44 and H50 (Fig. 2). These data
suggest that HCV may enter target cells via a mechanism
similar to that used by other flaviviruses. However, it should be
noted that changes in E2661-HATMCT conformation after pH
5.0 treatment may be unrelated to an acid-mediated mode of
entry.
We were unable to demonstrate any E2661-HATMCT-medi-
ated cell-cell fusion (Fig. 4 and data not shown). However, the
conditions used in this assay, although compatible with influ-
enza virus HA-mediated fusion, might not support E2-medi-
ated fusion. The production of polykaryotic cells is dependent
upon the density of the fusion protein at the cell surface (5),
and the expression method used may not result in a sufficient
accumulation of cell surface E2661-HATMCT to support fusion.
Alternatively, the lipid composition of HEK and U87 cell
membranes may not be compatible with E2-mediated fusion
(12, 49). In any event, the lack of detectable polykaryons is not
definitive evidence that HCV E2 does not have a fusogenic
activity, since variant influenza viruses, herpesviruses, and
paramyxoviruses exist that do not cause syncytium formation
even though they are active in their fusion function (50). An-
other explanation is that E1 is required, or indeed is respon-
sible, for the fusion event. Since we were unable to demon-
strate any fusion activity for E2661-HATMCT, we examined the
sequence of E1 for a putative fusion peptide. Interestingly,
recombinant E1 protein is secreted when truncated after
amino acid 340, only if an internal deletion between residues
262 and 290 is also present (29). This internal deletion spans a
hydrophobic domain, possibly containing a fusion peptide, that
could act as a transmembrane anchor when E1 is truncated at
residue 340, preventing its secretion. Viral fusion peptides may
act as transmembrane anchor domains, converting normally
soluble proteins into membrane-bound ones (34). Most fusion
peptides are composed of 16 to 26 relatively hydrophobic
amino acids (50). The sequence of the internal hydrophobic
domain in E1 is relatively highly conserved, with changes usu-
ally being conservative (Fig. 6A) (25). Alignment of this region
of HCV E1 with the putative fusion peptide from flavivirus E
proteins (41) revealed several similarities (Fig. 6B). Two Cys
residues are completely conserved between all sequences an-
alyzed. The structural implications of this are unclear, but if
these residues were involved in disulfide bonds, the putative
fusion peptide may be constrained in some fashion. An Asp
residue is present in all the representative HCV sequences and
some of the flavivirus sequences. The presence of acidic resi-
dues in the fusion peptides of some low-pH-activated viral
fusion proteins has been noted previously (51). Two Gly resi-
dues are conserved within these putative fusion domains. The
Gly residues within the E1 sequences have a spacing similar to
that observed in the fusion peptides of the paramyxoviruses, at
positions 3, 7, and 12 and at positions 3, 7, and 13 for the
majority of HCV sequences analyzed to date (Fig. 6C). In the
paramyxovirus F proteins, the Gly residues are believed to be
important for the structure of the fusion peptide (19). Given
the similarities between the internal hydrophobic region of
HCV E1, the putative (flavivirus) and known (paramyxovirus)
fusion peptides, we propose that this region may comprise the
HCV fusion peptide.
Some enveloped viruses are promiscuous in regard to the
proteins they will incorporate into their membrane, while oth-
ers appear to use specific signals in the sequences of their
envelope proteins to discriminate between viral and cellular
proteins present at the site of budding. Influenza virus appears
to utilize transmembrane and cytoplasmic tail sequences to
select its major envelope protein, HA, during particle forma-
tion (31). Hence, it is not surprising that E2 expressing the
HATMCT was incorporated efficiently into influenza virus par-
ticles (Fig. 5). In contrast, VSV has the capacity to incorporate
foreign gps regardless of their amino acid sequence (44) and
has been used extensively to study many viral gps. VSV parti-
cles expressing either chimeric HCV E1 or E2 gps were re-
cently reported to confer VSV entry, suggesting that the gps
could function independently to mediate binding and entry
into target cells (22). The entry of these pseudotyped viruses
could be inhibited by sera from chimpanzees immunized with
the homologous HCV gps; however, the entry was not shown
FIG. 5. Incorporation of E2661-HATMCT into influenza virus particles.
COS-7 cells were either mock transfected or transfected with pE2661-HATMCT
and infected at 24 h posttransfection with A/PR/8/34. Virus was harvested and
purified 24 h postinfection and analyzed by SDS-PAGE (15% polyacrylamide)
and immunoblotting for incorporation of the chimeric protein into particles. (A)
Immunoblotting for the presence of E2661-HATMCT with anti-E2 antibodies.
Lanes 1 and 2 are purified progeny virus released from mock-transfected cells
(lane 1) and cells transfected with pE2661-HATMCT (lane 2). Lanes 3 and 4 are
cell lysates prepared from mock-transfected COS-7 cells (lane 3) and COS-7 cells
transfected with pE2661-HATMCT (lane 4). (B) To confirm the presence of
influenza A virus particles, the same samples were analyzed by SDS-PAGE and
immunoblotting to detect M2, using the 14C2 MAb. (C) E2661-HATMCT derived
from a lysate of expressing cells (lane 1) and that incorporated into influenza
virus virions (lane 2) was compared by SDS-PAGE (10% polyacrylamide) fol-
lowed by immunoblotting with anti-E2 antibodies.
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to be CD81 dependent. Clearly, it will be important to dem-
onstrate whether CD81, either alone or with additional factors,
can function as the HCV receptor in allowing pseudotyped
virus-cell attachment and entry. Since CD81 is so widely ex-
pressed, it is unlikely to be the sole factor determining HCV
liver tropism. We are now in an ideal position to answer these
questions by studying the receptor requirements for attach-
ment, entry, and uncoating of influenza viruses expressing chi-
meric HCV gps.
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